PreceDo has established three core organoid technology platforms: normal organoid-based toxicity evaluation, tumor organoid-based efficacy assessment, and organoid-immune co‑culture systems, providing clinically relevant models to support drug development, precision medicine, and translational research.

1. Organoid-Based Toxicity Evaluation

Approximately 30% of drug candidates fail during clinical trials due to toxicity not detected in preclinical studies, with hepatotoxicity and cardiotoxicity being the leading causes. Organoid technology offers a more physiologically relevant platform for toxicity evaluation, bridging the gap between traditional models and human responses.

PreceDo has developed a comprehensive library of normal tissue-derived organoids (oral mucosa, lung, skin) and iPSC-derived organoids (liver, intestine, kidney, lung, brain, cardiac) to test drug-induced toxicity in vitro, supporting early safety screening and toxicology studies.

Key Advantages:

• Human-Relevant Background : Derived from healthy donor tissues, providing more accurate prediction of human drug toxicity
• Multi-Organ Coverage: Supports evaluation of hepatotoxicity, nephrotoxicity, gastrointestinal toxicity, pulmonary toxicity, and more 
• High-Throughput Screening: Compatible with 96/384 well formats for rapid, multi‑concentration screening
• Functional Relevance: Maintains organ-specific functions (e.g., CYP enzyme activity in liver, transporter activity in kidney)

2. Tumor Organoid-Based Efficacy Assessment

PreceDo has established a patient-derived organoid (PDO) biobank covering more than 20 cancer types, with ongoing expansion, delivering predictive data for drug development and clinical decision making.

Key Advantages:

• Multi-Dimensional Data: Maintains the original tumor’s mutation profile and phenotypic characteristics, integrating clinical, pathological, and drug response data
• Clinically Relevant: Drug responses correlate closely with patient outcomes
• Broad Cancer Coverage: Lung, colorectal, breast, gastric, pancreatic, ovarian, hematologic malignancies, and more
• Standardized Readouts: Provides IC50, combination indices, and other pharmacodynamic parameters

3. Organoid-Immune Co-Culture Models

PreceDo has developed a tumor organoid-immune co-culture platform that reconstructs the tumor‑immune microenvironment in vitro, enabling evaluation of immunotherapies—including immune checkpoint inhibitors, bispecific antibodies, and adoptive cell therapies.

Key Advantages:

• Recapitulates the Tumor Microenvironment : Models tumor-immune cell interactions
• Broad Immune Cell Compatibility: Supports PBMCs, T cells, NK cells, and CAR‑T cells
• Multi-Parameter Readouts: Assesses tumor cell killing, immune cell activation, and cytokine secretion
• Autologous Pairing:  Patient-matched tumor organoids and immune cells available